Melanoma
Conditions
Brief summary
Evaluation of safety and tolerability of four intradermal injections given at two week intervals. In addition the efficacy of transferrinfection was determined by quantifying Interleukin 2 (IL-2), which was locally produced by the implanted, transfected allogenic melanoma cells at the injection sites. Further determination of tumor specific and clinical host responses induced or augmented by the treatment were determined.
Interventions
BIOLOGICALBIBW2 component A
BIBW2 without IL-2 secreting cell line
BIOLOGICALBIBW2 component B
BIBW2 with IL-2 secreting cell line
Sponsors
Boehringer Ingelheim
Study design
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients who fail to respond to conventional therapy or for whom conventional therapy is not available * Metastatic melanoma (stage IV AJCC) which is surgically or medically incurable because of distant metastatic disease (i.e., a metastasis not in the same lymph node draining area as the primary malignant melanoma). Histologic confirmation of stage IV is required. Measurable disease that can be routinely assessed by physical examination and/or non-invasive radiological procedures * Karnofsky performance status is at least 60% and life expectancy greater than 4 months * Male or female, minimum age 18 years * Written informed consent of the patient in accordance with good clinical practice and local legislation * Availability of material for autologous Delayed Type Hypersensitivity (DTH) testing (material derived from autologous melanoma metastases and in-house preparation successful) is a requisite for entering the study * Patients have to undergo biopsy of at least one metastasis before the first and after the last vaccination
Exclusion criteria
* Patient who have received any chemotherapy, corticosteroids, radiotherapy (stereotactic irradiation permitted), immunotherapy (e.g. Granulocyte Macrophage Colony Stimulating Factor, Granulocyte Colony Stimulating Factor) or any other investigational drugs in the 4 weeks prior to the first vaccination or prior to surgical removal of tumor specimens for DTH material preparation (patients are not permitted to receive such therapies 4 weeks prior to first cell inoculation except of tumor reductive surgery which are medically indicated) * Patients with active intracranial metastases (CT/MRI) or choroidal melanoma * Patients with active autoimmune disease * Patients with organ allografts * Patients with evidence of one or more of the following infections: HIV-1, HIV-2, Hepatitis B Virus, Hepatitis C Virus, Human T lymphotropic Virus-1 * Patients with active systemic infections or other major medical illness of the cardiovascular organ system \[e.g. coronary heart disease (New York Heart Association class III or IV), history of clinically significant ventricular arrhythmias or angina\], coagulation disorder, respiratory or nervous system disorder or with severe endocrinological disease * Women of childbearing potential with a positive pregnancy test or without appropriate contraception (e.g. IUD \[ Intra-Uterine Device\], oral contraceptives) until at least 28 days after the last vaccination * Lactating women * Impaired renal or hepatic function (serum creatinine \> 1.5 mg/dl or creatinine clearance \< 75 ml/min). In amendments 1 and 3 serum creatinine levels were changed to 2.5 mg/dl and creatinine clearance was reduced to 30 ml/min * Impaired hematologic function with: * White Blood Count (WBC) \< 2500/mm\*\*3 or * absolute lymphocyte count \< 1500/mm\*\*3 or * hemoglobin \< 8 g/dl or * platelets \< 100,000/mm\*\*3 * Evidence for the existence or history of other malignant neoplasms (except adequately treated basal cell carcinoma and carcinoma in situ of the cervix)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Occurrence of dose limiting toxicity (DLT) | up to 6 weeks |
| Number of patients with adverse events | up to 28 days after the last vaccination |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of patients with delayed type hypersensitivity skin reaction | up to 28 days after the last vaccination | delayed type hypersensitivity testing |
| Number of antigen-positive cells in biopsies from metastatic lesions | up to 28 days after the last vaccination | — |
| Number of antigen-positive cells in the cellular infiltrate at the vaccination site | up to 28 days after the last vaccination | — |
| Number of patients with a positive reaction to Multitest Merieux | up to day 14 | positive reaction: sum of all indurations of all existing reactions =\> 10 mm (male) or \>= 5 mm (female) |
| Grading of local reactions on a 4-point-scale | up to 28 days after the last vaccination | — |
| Change in S-100 beta protein level in serum | up to 28 days after the last vaccination | — |
| Number of patients with clinical response | up to 28 days after the last vaccination | clinical response = complete and partial response |
| Change in interferon-gamma secretion as ratio of post-vaccination to pre-vaccination | up to 28 days after the last vaccination | — |
| Change in T cell proliferation as ratio of post-vaccination to pre-vaccination | up to 28 days after the last vaccination | — |
| Number of patients with IL-2 transcripts in biopsies of injection sites | 4-6 and 48 hours after first vaccination | — |
Outcome results
None listed